BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reed J, Bain S, Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1. F1000Res 2020;9:F1000 Faculty Rev-239. [PMID: 32269764 DOI: 10.12688/f1000research.20602.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes 2021;14:3567-602. [PMID: 34413662 DOI: 10.2147/DMSO.S319895] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Liu XY, Zhang N, Zhang SX, Xu P. Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1. Eur J Neurosci 2021;54:7749-69. [PMID: 34676939 DOI: 10.1111/ejn.15502] [Reference Citation Analysis]
3 Tsai W, Sung F, Chiu L, Shih Y, Tsai M, Wu S. Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study. Front Pharmacol 2022;13:765446. [DOI: 10.3389/fphar.2022.765446] [Reference Citation Analysis]
4 Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R, Bismuth K, Berenbaum F. Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity? Journal of Orthopaedic Translation 2022;32:121-9. [DOI: 10.1016/j.jot.2022.02.001] [Reference Citation Analysis]
5 Seon MJ, Hwang SY, Son Y, Song J, Kim OY. Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women. Nutrients 2021;13:865. [PMID: 33800785 DOI: 10.3390/nu13030865] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kim YK, Kim OY, Song J. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front Pharmacol 2020;11:1270. [PMID: 32922295 DOI: 10.3389/fphar.2020.01270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Tian MM, Li YX, Liu S, Zhu CH, Lan XB, Du J, Ma L, Yang JM, Zheng P, Yu JQ, Liu N. Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components. Molecules 2021;27:255. [PMID: 35011486 DOI: 10.3390/molecules27010255] [Reference Citation Analysis]
8 Mishra V, Nayak P, Sharma M, Albutti A, Alwashmi ASS, Aljasir MA, Alsowayeh N, Tambuwala MM. Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update. Pharmaceutics 2021;13:1568. [PMID: 34683861 DOI: 10.3390/pharmaceutics13101568] [Reference Citation Analysis]
9 Tashiro H, Shore SA. The Gut Microbiome and Ozone-induced Airway Hyperresponsiveness. Mechanisms and Therapeutic Prospects. Am J Respir Cell Mol Biol 2021;64:283-91. [PMID: 33091322 DOI: 10.1165/rcmb.2020-0288TR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C. Therapeutic peptides: current applications and future directions. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00904-4] [Reference Citation Analysis]
11 Eliaschewitz FG, Canani LH. Advances in GLP-1 treatment: focus on oral semaglutide. Diabetol Metab Syndr 2021;13:99. [PMID: 34526121 DOI: 10.1186/s13098-021-00713-9] [Reference Citation Analysis]
12 Ding Y, Zhang H, Zhu X, Wu M, Yang L, Yao Z, Xie Q, Liu X, Li C. Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects. Expert Opin Investig Drugs 2021;:1-8. [PMID: 34793265 DOI: 10.1080/13543784.2021.2008906] [Reference Citation Analysis]